",n.parentNode.insertBefore(a,n)};if(!!document.cookie.match(/cookieConsent=true/))window.gaf(); ',{'forceSSL':true});

about us

Kalos (kā-lōs)

adverb greek 

meaning health; well

Kalos Therapeutics, founded in 2005, is a human and animal life science company that builds on the company’s intellectual property and knowledge relating to a platform technology based on Atrial Natriuretic Peptide (ANP).  In human clinical studies, our initial targets of pancreatic and ovarian cancer are considered orphan diseases with unmet clinical needs, which allows Kalos to seek rapid review and a faster approval. Kalos expects to secure the ‘Breakthrough Technology’ designation by the FDA, which will also shorten the review and approval process. 

Kalos also is focused on therapeutic approaches to retinal diseases. This technology leverages our therapeutic cell signaling power, which blocks VEGF signaling in wet Age-related Macular Degeneration (AMD). An additional effect triggers immunologic processes that remove the dead cellular debris while ending the formation of frail capillaries that lead to blindness. This therapeutic application can enhance the treatment of orphan diseases in this space, such as diabetic macular edema. 

Our animal health leverages the diuretic and therapeutic effects of ANP to replace Lasix (furosemide), banned as a race day medication in Thoroughbred racehorses and other competition horses. The equine market is over a billion dollars per annum globally, and revenue for our animal health division is anticipated within two calendar years.

Kalos peptides inhibited up to 40% of COV-2 spike peptides from its binding domain in the ACE receptor, demonstrating a peptide-peptide interaction producing inhibition. This ability to treat very ill patients who are hospitalized and dosed intravenously is an advance for treating this disease in all patients.

© 2020 Kalos Therapeutics. All Rights Reserved.

This website makes use of cookies. Please see our privacy policy for details.